Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

By sjmartinez • September 24, 2024

André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Ann Oncol. 2024 Sep 21:S0923-7534(24)04018-3. doi: 10.1016/j.annonc.2024.09.010. Epub ahead of print. PMID: 39313156.

Tags: acquired resistance, Advanced breast cancer, biomarkers, CDK4/6 inhibitor, Hematology/Oncology, Publications, ribociclib

Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer

Orr LD, Vanderpoel J, Vadagam P, Patel MI, Roy UB, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Patient, care partner,[...]

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin[...]

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]